1 active not recruiting, 1 not yet recruiting. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow CMS: new trials by email Literature Review of CMS trials Research Report on CMS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) Adimanebart IV, Placebo IV - Congenital Myasthenic Syndrome, CMS | Phase 3 | Not yet recruiting | argenx | 105 | 2026-09-01 | 2026-10-19 |
| A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) ARGX-119, Placebo - Congenital Myasthenic Syndrome, CMS | Phase 1 | Active not recruiting | argenx | 15 | 2024-09-24 | 2026-07-24 |
Myasthenic Syndromes, Congenital (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Nervous System Diseases (2) · Neuromuscular Diseases (2) · Neuromuscular Junction Diseases (2)
argenx (2)
Canada (1) · France (1) · Italy (1) · Spain (1) · United Kingdom (1) · United States (1)
2023 (1), 2025 (1)